A letter to the Croton Planning Board opposing approval of a cannabis dispensary in the village.
Community opposition medical cannabis often stems from stigma and misinformation affecting patient access. Understanding these barriers helps clinicians support their patients better. This article discusses local resistance to cannabis dispensaries and…
Latest EU Assessment on the Safety of Carbon Dioxide Extract from Cannabis sativa L.
The latest EU assessment highlights concerns about carbon dioxide extract cannabis safety as a novel food ingredient. This regulatory uncertainty affects clinical dosing and product quality standards. Physicians should prioritize medical-grade cannabis…
North Carolina advisory group recommends legalizing marijuana for adults – WXII
The North Carolina cannabis legalization advisory group recommends legalizing marijuana for adults under a regulated framework. This policy shift aims to improve patient access and product safety. Clinicians should prepare for new clinical guidance as…
Massachusetts Cannabis Reform Bill Expected to Pass Legislature
Massachusetts cannabis reform legislation 2026 is expected to pass both the House and Senate, reshaping the state's cannabis regulatory landscape. This legislation will influence clinical practice by clarifying prescribing pathways and product safety…
NC Council Advocates Legal Marijuana and Hemp to Address Illegal Use
The NC cannabis legalization update highlights the council's call for regulated marijuana and hemp markets. This approach aims to reduce illegal use and enhance product safety. It reflects a shift toward public health-focused cannabis policies in North…
Missouri’s $100 Million Marijuana Tax Revenue Sits Unused Despite Voter Mandate
Missouri’s marijuana tax revenue allocation remains delayed, leaving nearly $100 million unused despite voter mandates. This delay impacts healthcare access and substance abuse treatment programs dependent on these funds. Understanding marijuana tax…
CED Regulatory Digest: Latest Cannabinoid Labeling Guidance Updates
This CED Regulatory Digest covers the latest cannabinoid labeling guidance updates from the FDA docket. It highlights key compliance posture changes and agency comment reviews. Stay informed on regulatory developments affecting cannabinoid products.
DEA Synthetic Opioid Scheduling Updates March 2026
This update covers DEA synthetic opioid scheduling and regulatory changes relevant to cannabis clinicians. The focus is on new Schedule I placements and their clinical implications. These regulatory updates inform patient care and research considerations.
DEA Scheduling Synthetic Drugs: March 12, 2026 Updates
The March 12, 2026 update covers DEA scheduling synthetic drugs and related regulatory affairs. This includes synthetic opioids and marijuana rescheduling proposals. Clinicians should note implications for controlled substances management.
Marijuana Rescheduling: Key Regulatory Updates March 2026
The marijuana rescheduling proposal is a key focus in the March 2026 regulatory updates. This change could impact cannabis clinical practice and research access. Marijuana rescheduling remains central to evolving federal cannabis policy.
